| Market Capitalization (Millions $) |
82,259 |
| Shares
Outstanding (Millions) |
106 |
| Employees |
15,410 |
| Revenues (TTM) (Millions $) |
15,535 |
| Net Income (TTM) (Millions $) |
4,329 |
| Cash Flow (TTM) (Millions $) |
955 |
| Capital Exp. (TTM) (Millions $) |
921 |
Business Description
Regeneron Pharmaceuticals Inc. Overview
Regeneron Pharmaceuticals Inc. is a prominent biotechnology company dedicated to the development and commercialization of innovative therapies intended to treat serious medical conditions. Founded in 1988, Regeneron has cemented its reputation in the biotech field, emerging as a leader recognized worldwide for its pioneering work in drug discovery and development.
Headquarters and Workforce
The companys headquarters is located in Tarrytown, New York, where it operates a significant 579-acre research and development facility. Employing over 8,000 individuals across diverse roles, including scientists, researchers, and clinicians, Regeneron boasts a collaborative work environment that fosters scientific innovation. The personnel are committed to advancing medical research and developing novel treatments, reflecting the company’s dedication to improving patient outcomes.
Research and Development Focus
Regeneron focuses on creating biologics, which are drugs derived from living organisms. This approach allows the company to leverage its proprietary technologies to develop highly effective and safe therapies. Their extensive R&D efforts concentrate on various therapeutic areas, including ophthalmology, dermatology, immunology, cancer, and infectious diseases.
Product Portfolio
Regenerons product lineup features several groundbreaking therapies targeting a range of medical conditions:
1. Eylea (aflibercept): One of Regeneron’s flagship products, Eylea is a vascular endothelial growth factor (VEGF) inhibitor used to treat various retinal diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), and other conditions. Eylea significantly improves vision outcomes in patients and has become a standard treatment in ophthalmology.
2. Dupixent (dupilumab): Developed in partnership with Sanofi, Dupixent is an injectable monoclonal antibody that treats moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. This drug has transformed the management of these chronic conditions, providing significant relief for patients suffering from severe allergic and inflammatory diseases.
3. REGEN-COV (casirivimab and imdevimab): In response to the COVID-19 pandemic, Regeneron quickly developed REGEN-COV, a monoclonal antibody cocktail that has shown effectiveness in reducing hospitalization and mortality rates in patients with COVID-19. The therapy received Emergency Use Authorization (EUA) by the FDA and has been utilized extensively during the pandemic.
4. Libtayo (cemiplimab): Libtayo is an anti-PD-1 monoclonal antibody approved for the treatment of advanced cutaneous squamous cell carcinoma and non-small cell lung cancer. It represents Regeneron’s foray into oncology, highlighting its commitment to treating various forms of cancer.
Collaborative Efforts and Expansion
Regeneron’s growth strategy often includes collaborations and partnerships. Working with other pharmaceutical and biotechnology companies, academic institutions, and healthcare providers, Regeneron aims to enhance its research capabilities, accelerate the development of new therapies, and improve patient access to its medications.
In addition to its strong R&D capabilities, Regeneron is also committed to manufacturing excellence, ensuring that its biologics can be produced at scale while maintaining quality and efficacy. The company has invested heavily in its manufacturing facilities, which are crucial for the supply of its therapies, particularly in times of heightened global demand, such as during the COVID-19 pandemic.
Investment in Innovation
Regeneron continually invests in cutting-edge technology, including genetic and genomic research, to identify new drug targets and develop personalized medicine approaches. The company is also involved in advanced biomanufacturing techniques and the use of artificial intelligence in drug discovery, demonstrating its commitment to maintaining a leadership position in biotech innovation.
Conclusion
In summary, Regeneron Pharmaceuticals Inc. is a trailblazer in biotechnology, dedicated to advancing treatments for serious medical conditions through rigorous research and development. With a robust product portfolio, significant investments in R&D and manufacturing, and a commitment to collaboration, Regeneron continues to play a vital role in enhancing patient care and outcomes in various therapeutic areas. Its ongoing efforts not only illustrate the company’s commitment to innovative medicine but also underscore its status as a key player in the global healthcare landscape.
Company Address: 777 Old Saw Mill River Road Zagreb 10591 City of Zagreb
Company Phone Number: 847-7000 Stock Exchange / Ticker: NASDAQ REGN
|
5.73% 
35.76 %